ArticleBMC complementary medicine and therapies2025
Antimicrobial, antibiofilm, cytotoxicity, and substantivity of aged garlic extract against oral bacteria: an in-vitro study.
Article in BMC complementary medicine and therapies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGarlic (Allium sativum L.) is a powerful antimicrobial, antioxidant, and anti-inflammatory agent. Aged garlic has more antioxidant and antimicrobial properties compared to fresh garlic. Garlic has been used for the treatment of many oral and periodontal diseases. However, the efficacy of aged garlic extract (AGE) against periodontal pathogens has never been explored. Hence, this in vitro study aims to assess the antimicrobial, antibiofilm, substantivity, and cytotoxic properties of AGE against key periodontal pathogens and oral tissues.
methodsThe antimicrobial properties of the AGE were evaluated by assessing the minimal bactericidal concentration (MBC) and minimal inhibitory concentration (MIC) against Actinomyces viscosus, Streptococcus salivarius, Fusobacterium nucleatum, Prevotella intermedia, Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Tannerella forsythia compared to doxycycline and chlorhexidine using the serial dilution method. The antibiofilm properties of AGE were checked for A. actinomycetemcomitans, and F. nucleatum was checked using the standard crystal violet staining assay. The cytocompatibility was checked against human-derived gingival and periodontal fibroblasts and modified oral keratinocytes using 3-4-5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide (MTT) assay. The substantivity of the extract was checked against chlorhexidine on the dentin surface from extracted tooth samples using an ultraviolet spectrophotometer.
resultsThe growth of A. viscosus, F. nucleatum, and S. salivarius was inhibited by AGE at 50 µg/ml. At 25 µg/ml, P. gingivalis and A. actinomycetemcomitans were inhibited. P. intermedia growth required a higher concentration of 100 µg/ml. At 25 µg/ml and 100 µg/ml, AGE showed bactericidal activity against A. viscosus and P. intermedia, respectively. The anti-biofilm assay showed that the percentage inhibition was 37.99% for F. nucleatum and 2.52% for A. actinomycetemcomitans. The cell viability of gingival fibroblasts (90%) and modified human keratinocytes (80%) was maintained by AGE at concentrations of 2.5 mg/ml and 5 mg/ml, respectively. The mean difference in substantivity for chlorhexidine and AGE at one minute was statistically significant (p = 0.0112).
conclusionAGE was effective in inhibiting the growth of periodontal pathogens. However, its antimicrobial effects were not statistically significant when compared to doxycycline. AGE is biocompatible with gingival and periodontal ligament fibroblasts and has good substantivity to the dentin surface.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.